Stocks · News reference
Lisata Therapeutics Announces Suit Against Kuva Labs Seeking Damages And $2M Termination Fee; Cuts Approximately 72% Of Full-Time Employees
Lisata has filed suit in the Delaware Court of Chancery against Kuva over Kuva’s breach of the previously-disclosed Agreement and Plan of Merger dated March 6, 2026 (as amended, the "Merger Agreement"), seeking,
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 4, 2026, 11:14 AM
- Checked
- Aug 4, 2026, 11:14 AM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Lisata Therapeutics shares are trading lower after the company announced it has terminated its merger agreement with Kuva Labs.
Read original at benzingaLisata Therapeutics Terminates Merger Agreement With Kuva Labs; Termination Due To Kuva Labs' Failure To Obtain Financing, Accept Tendered Shares; Board To Carry Out Strategic Options Including Asset Sale
https://www.sec.gov/ix?doc=/Archives/edgar/data/320017/000114036126029541/ef20078724_8k.htm
Read original at benzinga